BRPI0513812B8 - método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical - Google Patents

método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical

Info

Publication number
BRPI0513812B8
BRPI0513812B8 BRPI0513812A BRPI0513812A BRPI0513812B8 BR PI0513812 B8 BRPI0513812 B8 BR PI0513812B8 BR PI0513812 A BRPI0513812 A BR PI0513812A BR PI0513812 A BRPI0513812 A BR PI0513812A BR PI0513812 B8 BRPI0513812 B8 BR PI0513812B8
Authority
BR
Brazil
Prior art keywords
radical
composition
hyperpolarized
pyruvate
producing
Prior art date
Application number
BRPI0513812A
Other languages
English (en)
Inventor
Thaning Mikkel
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0513812A publication Critical patent/BRPI0513812A/pt
Publication of BRPI0513812B1 publication Critical patent/BRPI0513812B1/pt
Publication of BRPI0513812B8 publication Critical patent/BRPI0513812B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Rectifiers (AREA)

Abstract

método para produzir uma composição líquida que compreende ¹³c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical a invenção diz respeito a um método de produzir uma composição que compreende ¹³c-piruvato hiperpolarizado, à composição e seu uso como um agente formador de imagem para a formação de imagem rm.
BRPI0513812A 2004-07-30 2005-07-28 método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical BRPI0513812B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20043229 2004-07-30
PCT/NO2005/000281 WO2006011809A1 (en) 2004-07-30 2005-07-28 Method of producing a composition, composition and its use

Publications (3)

Publication Number Publication Date
BRPI0513812A BRPI0513812A (pt) 2008-05-13
BRPI0513812B1 BRPI0513812B1 (pt) 2017-05-09
BRPI0513812B8 true BRPI0513812B8 (pt) 2021-07-27

Family

ID=35058362

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513812A BRPI0513812B8 (pt) 2004-07-30 2005-07-28 método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical

Country Status (18)

Country Link
US (2) US20080095713A1 (pt)
EP (1) EP1797102B1 (pt)
JP (2) JP5367265B2 (pt)
KR (2) KR20070063504A (pt)
CN (1) CN101035796B (pt)
AU (1) AU2005267668B2 (pt)
BR (1) BRPI0513812B8 (pt)
CA (1) CA2575601C (pt)
DK (1) DK1797102T3 (pt)
ES (1) ES2545260T3 (pt)
HK (1) HK1107691A1 (pt)
IL (1) IL180897A (pt)
MX (1) MX2007001035A (pt)
NZ (1) NZ552898A (pt)
PL (1) PL1797102T3 (pt)
RU (1) RU2374252C2 (pt)
WO (1) WO2006011809A1 (pt)
ZA (1) ZA200701271B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014463D0 (en) * 2000-06-14 2000-08-09 Nycomed Amersham Plc NMR Method
KR20070063504A (ko) * 2004-07-30 2007-06-19 지이 헬스케어 에이에스 조성물의 제조 방법, 조성물 및 그의 용도
EP1954321B1 (en) * 2005-12-01 2011-11-23 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) using a trityl radical and a paramagnetic metal ion
WO2007069909A2 (en) * 2005-12-16 2007-06-21 Ge Healthcare As Method to produce hyperpolarised carboxylates of organic amines
CN101415446A (zh) * 2006-03-29 2009-04-22 通用电气医疗集团股份有限公司 生产超极化的羧酸盐和磺酸盐的方法
JP5269791B2 (ja) 2006-08-30 2013-08-21 ジーイー・ヘルスケア・アクスイェ・セルスカプ 動的核分極（ｄｎｐ）方法並びに該方法で使用するための化合物及び組成物
WO2008086534A1 (en) 2007-01-11 2008-07-17 Huntington Medical Research Institutes Imaging agents and methods of use thereof
US8731640B2 (en) 2007-03-28 2014-05-20 General Electric Company Fluid path system for dissolution and transport of a hyperpolarized material
US20080240998A1 (en) * 2007-03-28 2008-10-02 Urbahn John A Fluid path system for dissolution and transport of a hyperpolarized material
US7470813B2 (en) 2007-03-30 2008-12-30 Ge Healthcare Limited Method for the production of pyruvic acid
CA2683023C (en) * 2007-05-17 2016-10-11 General Electric Company Mr methods of grading a tumor using an imaging medium that comprises hyperpolarized 13c-pyruvate
US9227173B2 (en) 2007-06-22 2016-01-05 General Electric Company Methods for dynamic filtration of pharmaceutical products
EP2170407A2 (en) * 2007-07-26 2010-04-07 GE Healthcare UK Limited Imaging medium comprising hyperpolarised 13c-lactate and use thereof
EP2902041A1 (en) 2007-12-19 2015-08-05 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
ES2379143T3 (es) * 2007-12-21 2012-04-23 Ge Healthcare Limited Agente de obtención de imágenes por RM, medio de obtención de imágenes y procedimientos para la obtención de imágenes en los que se utiliza dicho medio de obtención de imágenes
WO2009129265A1 (en) 2008-04-14 2009-10-22 Huntington Medical Research Institutes Methods and apparatus for pasadena hyperpolarization
US8763410B2 (en) 2008-04-21 2014-07-01 General Electric Company Method and apparatus for the dissolution and filtration of a hyperpolarized agent with a neutral dissolution media
CN102083470B (zh) 2008-05-02 2015-05-20 通用电气公司 应用超极化13c-丙酮酸盐,通过13c-mr检测测定丙氨酸转氨酶(alt)活性的方法
RU2543704C2 (ru) 2009-04-02 2015-03-10 ДжиИ ХЕЛТКЕР ЛИМИТЕД Применение магнитно-резонансной визуализирующей среды, содержащей гиперполяризованный 13с-пируват, для обнаружения воспаления или инфекции
JP5744032B2 (ja) 2009-09-10 2015-07-01 ジーイー・ヘルスケア・リミテッド 過分極１３ｃ−フルクトースを用いる１３ｃ−ｍｒ検出
DE102009054956A1 (de) * 2009-12-18 2011-06-22 Siemens Aktiengesellschaft, 80333 Magnetresonanztomographie-Bildgebung
CN102892434B (zh) 2010-04-08 2014-11-19 伯拉考成像股份公司 制备超极化底物的方法和mri方法
US9259490B2 (en) 2010-05-03 2016-02-16 Ge Healthcare Limited Hyperpolarized lactate contrast agent for determination of LDH activity
US20130149250A1 (en) * 2011-06-23 2013-06-13 The Regents Of The University Of California Hyperpolarized agents for mri characterization of redox systems in vivo
US9511154B2 (en) 2011-10-12 2016-12-06 Bracco Imaging S.P.A. Process for the preparation of hyperpolarized derivatives for use in MRI analysis
EP2788035B1 (en) 2011-12-05 2016-03-09 Bracco Imaging S.p.A Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation mri analysis
JP6507101B2 (ja) 2013-01-31 2019-04-24 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． Ｍｒにおける代謝マーカーとしての過分極エステル
WO2015000838A1 (en) 2013-07-01 2015-01-08 Bracco Imaging Spa Hyperpolarized 1-13c-1,1-bis(acetoxy(methyl))-2,2'-cyclopropane as metabolic marker for mr
US9874622B2 (en) 2013-09-27 2018-01-23 General Electric Company Hyperpolarized media transport vessel

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61448B1 (en) 1987-06-23 1994-11-02 Hafslund Nycomed Innovation Improvements in and relating to magnetic resonance imaging
GB8817137D0 (en) 1988-07-19 1988-08-24 Nycomed As Compositions
EP0515458B1 (en) 1990-02-12 1995-08-23 Nycomed Innovation AB Triarylmethyl radicals and the use of inert carbon free radicals in mri
DK0662004T3 (da) 1991-08-09 1998-10-19 Nycomed Innovation Ab Anvendelse af stabile frie radikaler ved magnetiskresonans-billeddannnelse
US5728370A (en) 1993-04-02 1998-03-17 Nycomed Imaging As Free Radicals
EP0871896B1 (en) 1995-09-08 2002-01-30 Nycomed Imaging AS A method of determining oxygen concentration in a sample
WO1998039277A1 (en) 1997-03-06 1998-09-11 Nycomed Imaging As Triarylmethyl free radicals as image enhancing agents
AU8119298A (en) 1997-06-19 1999-01-04 Nycomed Imaging As Overhauser magnetic resonance imaging (ormi) method comprising ex vivo polarization of a magnetic resonance (mr) imaging agent
US6278893B1 (en) * 1998-01-05 2001-08-21 Nycomed Imaging As Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent
US6232497B1 (en) 1998-12-23 2001-05-15 Skw Trostberg Aktiengesellschaft Method for producing alkali metal and alkaline earth metal pyruvates
GB0014463D0 (en) * 2000-06-14 2000-08-09 Nycomed Amersham Plc NMR Method
CN100392422C (zh) 2000-11-03 2008-06-04 通用电气医疗集团股份有限公司 为nmr分析溶解超极化固体材料的方法和装置
US6617169B2 (en) * 2001-03-30 2003-09-09 Mclean Hospital Corporation Two-dimensional MR spectroscopy techniques
US6486671B1 (en) * 2001-05-14 2002-11-26 Ge Medical Systems Global Technologies Company Llc MRI image quality improvement using matrix regularization
US6958244B2 (en) * 2002-04-12 2005-10-25 Bruker Biospin Corp. Low-conductivity buffers for magnetic resonance measurements
KR20070063504A (ko) * 2004-07-30 2007-06-19 지이 헬스케어 에이에스 조성물의 제조 방법, 조성물 및 그의 용도
WO2006011811A2 (en) * 2004-07-30 2006-02-02 Ge Healthcare As Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process

Also Published As

Publication number Publication date
IL180897A (en) 2010-11-30
PL1797102T3 (pl) 2015-10-30
WO2006011809A1 (en) 2006-02-02
NZ552898A (en) 2011-02-25
CN101035796A (zh) 2007-09-12
JP2012236832A (ja) 2012-12-06
EP1797102A1 (en) 2007-06-20
JP5745470B2 (ja) 2015-07-08
ZA200701271B (en) 2008-05-28
EP1797102B1 (en) 2015-05-27
KR20130028989A (ko) 2013-03-20
RU2374252C2 (ru) 2009-11-27
RU2007102843A (ru) 2008-09-10
KR20070063504A (ko) 2007-06-19
KR101475635B1 (ko) 2014-12-22
CA2575601C (en) 2013-05-28
ES2545260T3 (es) 2015-09-09
US9023320B2 (en) 2015-05-05
US20080213186A1 (en) 2008-09-04
AU2005267668A1 (en) 2006-02-02
CN101035796B (zh) 2011-06-22
CA2575601A1 (en) 2006-02-02
JP2008508266A (ja) 2008-03-21
BRPI0513812A (pt) 2008-05-13
MX2007001035A (es) 2007-07-11
IL180897A0 (en) 2007-07-04
AU2005267668B2 (en) 2011-10-20
US20080095713A1 (en) 2008-04-24
DK1797102T3 (en) 2015-08-24
BRPI0513812B1 (pt) 2017-05-09
HK1107691A1 (en) 2008-04-11
JP5367265B2 (ja) 2013-12-11

Similar Documents

Publication Publication Date Title
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
PE20142371A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
BRPI0612674B8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
BRPI0817482B8 (pt) uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BRPI0507684A (pt) agentes de contraste para formação de imagem de perfusão miocárdica
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
ECSP088296A (es) Compuestos terapéuticos
BR112018073298A2 (pt) cápsula, suspensão de cápsula, mistura, uso das cápsulas e método para reduzir a nitrificação
CL2006002332A1 (es) Metodo para preparar una composicion medica que comprende preparar una composicion para tratamiento y agregar al menos un agente a dicha composicion, en donde los agentes tienen la propiedad de aumentar o al menos mantener la viscosidad de la composi
CY1118835T1 (el) Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07D 519/00 (2006.01), A61B 5/055 (2006.01), A61K

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2630 DE 01-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.